GlaxoSmithKline Talks Up Its Pipeline
Published: Feb 06, 2014
Drugs giant GlaxoSmithKline (LON:GSK) expects core earnings to grow by 4-8% this year on a constant exchange rates (CER) basis.
The group issued the guidance as it published fourth quarter and full year results that showed fourth quarter earnings per share in the core business rose 1% on a CER basis from a year earlier.
Help employers find you! Check out all the jobs and post your resume.